137 related articles for article (PubMed ID: 18212197)
1. In vivo proton spectroscopy of giant cell tumor of the bone.
Sah PL; Sharma R; Kandpal H; Seith A; Rastogi S; Bandhu S; Jagannathan NR
AJR Am J Roentgenol; 2008 Feb; 190(2):W133-9. PubMed ID: 18212197
[TBL] [Abstract][Full Text] [Related]
2. Study of single voxel 1H MR spectroscopy of bone tumors: differentiation of benign from malignant tumors.
Zhang J; Cheng K; Ding Y; Liang W; Ding Y; Vanel D; Cheng X
Eur J Radiol; 2013 Dec; 82(12):2124-8. PubMed ID: 22169357
[TBL] [Abstract][Full Text] [Related]
3. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
[TBL] [Abstract][Full Text] [Related]
4. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy.
Fayad LM; Barker PB; Jacobs MA; Eng J; Weber KL; Kulesza P; Bluemke DA
AJR Am J Roentgenol; 2007 Jun; 188(6):1513-20. PubMed ID: 17515370
[TBL] [Abstract][Full Text] [Related]
5. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results.
Wang CK; Li CW; Hsieh TJ; Chien SH; Liu GC; Tsai KB
Radiology; 2004 Aug; 232(2):599-605. PubMed ID: 15286325
[TBL] [Abstract][Full Text] [Related]
6. Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification.
Lee CW; Lee JH; Kim DH; Min HS; Park BK; Cho HS; Kang HG; Suh JS; Ehara S
Clin Imaging; 2010; 34(1):47-52. PubMed ID: 20122519
[TBL] [Abstract][Full Text] [Related]
7. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
Bartella L; Morris EA; Dershaw DD; Liberman L; Thakur SB; Moskowitz C; Guido J; Huang W
Radiology; 2006 Jun; 239(3):686-92. PubMed ID: 16603660
[TBL] [Abstract][Full Text] [Related]
8. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX
Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615
[TBL] [Abstract][Full Text] [Related]
9. Contrast/Noise ratio on conventional MRI and choline/creatine ratio on proton MRI spectroscopy accurately discriminate low-grade from high-grade cerebral gliomas.
Fayed N; Morales H; Modrego PJ; Pina MA
Acad Radiol; 2006 Jun; 13(6):728-37. PubMed ID: 16679275
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of musculoskeletal tumors by proton MR spectroscopy.
Fayad LM; Barker PB; Bluemke DA
Semin Musculoskelet Radiol; 2007 Sep; 11(3):240-5. PubMed ID: 18260034
[TBL] [Abstract][Full Text] [Related]
11. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy.
Sardanelli F; Fausto A; Di Leo G; de Nijs R; Vorbuchner M; Podo F
AJR Am J Roentgenol; 2009 Jun; 192(6):1608-17. PubMed ID: 19457825
[TBL] [Abstract][Full Text] [Related]
12. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
Fayed N; Dávila J; Medrano J; Olmos S
Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of choline measurement by proton MR spectroscopy in patients with malignant tumors.
Lee J; Yamaguchi T; Abe A; Shizukuishi K; Uemura H; Miyagi E; Sakata K; Inoue T
Radiat Med; 2004; 22(3):148-54. PubMed ID: 15287529
[TBL] [Abstract][Full Text] [Related]
14. The role of MRS in the differentiation of benign and malignant soft tissue and bone tumors.
Doganay S; Altinok T; Alkan A; Kahraman B; Karakas HM
Eur J Radiol; 2011 Aug; 79(2):e33-7. PubMed ID: 21376496
[TBL] [Abstract][Full Text] [Related]
15. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy--initial results.
Yeung DK; Cheung HS; Tse GM
Radiology; 2001 Jul; 220(1):40-6. PubMed ID: 11425970
[TBL] [Abstract][Full Text] [Related]
16. 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors.
Tozaki M; Hoshi K
AJR Am J Roentgenol; 2010 May; 194(5):1384-90. PubMed ID: 20410429
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive evaluation of cerebral glioma grade by using multivoxel 3D proton MR spectroscopy.
Zeng Q; Liu H; Zhang K; Li C; Zhou G
Magn Reson Imaging; 2011 Jan; 29(1):25-31. PubMed ID: 20832225
[TBL] [Abstract][Full Text] [Related]
18. The value of proton MR-spectroscopy in the differentiation of brain tumours from non-neoplastic brain lesions.
Aydin H; Sipahioğlu S; Oktay NA; Altin E; Kizilgöz V; Hekimoglu B
JBR-BTR; 2011; 94(1):1-10. PubMed ID: 21466053
[TBL] [Abstract][Full Text] [Related]
19. Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy.
Bartella L; Thakur SB; Morris EA; Dershaw DD; Huang W; Chough E; Cruz MC; Liberman L
Radiology; 2007 Oct; 245(1):80-7. PubMed ID: 17885182
[TBL] [Abstract][Full Text] [Related]
20. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner.
Kuo YT; Li CW; Chen CY; Jao J; Wu DK; Liu GC
J Magn Reson Imaging; 2004 May; 19(5):598-604. PubMed ID: 15112309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
